• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Enliven Therapeutics Inc.

    7/29/24 6:12:42 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELVN alert in real time by email
    SC 13D/A 1 tm2420416d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

    Enliven Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    29337E102

    (CUSIP Number)

     

    5AM Venture Management, LLC

    Attn: Paul A. Stone, Chief Legal Officer

    4 Embarcadero Center, Suite 3110

    San Francisco, CA 94111

    (415) 993-8565

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    July 25, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    5AM Ventures VI, L.P.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    WC

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    1,922,673 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    1,922,673 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,922,673 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    4.1% (3)

    14.

    Type of Reporting Person (See Instructions)

    PN

           

    (1)This Schedule 13D is filed by 5AM Ventures VI, L.P. (“Ventures VI”), 5AM Partners VI, LLC (“Partners VI”), 5AM Opportunities I, L.P. (“Opportunities”), 5AM Opportunities I (GP), LLC (“Opportunities GP”), Andrew J. Schwab (“Schwab”) and Dr. Kush Parmar (“Parmar” and, with Ventures VI, Partners VI, Opportunities, Opportunities GP and Schwab, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)The shares are directly held by Ventures VI. Partners VI serves as sole general partner of Ventures VI and Schwab and Parmar are managing members of Partners VI. Each of Partners VI, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI.

     

    (3)This percentage is calculated based upon 47,036,698 shares of Common Stock outstanding as of May 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 14, 2024.

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    5AM Partners VI, LLC

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    1,922,673 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    1,922,673 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,922,673 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    4.1% (3)

    14.

    Type of Reporting Person (See Instructions)

    OO

           

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)The shares are directly held by Ventures VI. Partners VI serves as sole general partner of Ventures VI and Schwab and Parmar are managing members of Partners VI. Each of Partners VI, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI.

     

    (3)This percentage is calculated based upon 47,036,698 shares of Common Stock outstanding as of May 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024.

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    5AM Opportunities I, L.P.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    WC

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    381,659 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    381,659 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    381,659 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    0.8% (3)

    14.

    Type of Reporting Person (See Instructions)

    PN

           

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)The shares are directly held by Opportunities. Opportunities GP serves as sole general partner of Opportunities and Schwab and Parmar are managing members of Opportunities GP. Each of Opportunities GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opportunities.

     

    (3)This percentage is calculated based upon 47,036,698 shares of Common Stock outstanding as of May 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024.

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    5AM Opportunities I (GP), LLC

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    381,659 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    381,659 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    381,659 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    0.8% (3)

    14.

    Type of Reporting Person (See Instructions)

    OO

           

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)The shares are directly held by Opportunities. Opportunities GP serves as sole general partner of Opportunities and Schwab and Parmar are managing members of Opportunities GP. Each of Opportunities GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opportunities.

     

    (3)This percentage is calculated based upon 47,036,698 shares of Common Stock outstanding as of May 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024.

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    Kush Parmar

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    2,304,332 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    2,304,332 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,304,332 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    4.9% (3)

    14.

    Type of Reporting Person (See Instructions)

    IN

           

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)Includes (i) 1,922,673 shares of Common Stock held by Ventures VI and (ii) 381,659 shares of Common Stock held by Opportunities. Partners VI serves as the sole general partner of Ventures VI and Opportunities GP serves as the sole general partner of Opportunities. As managing members of each of Partners VI and Opportunities GP, Schwab and Parmar share voting and dispositive power over the shares held by each of Ventures VI and Opportunities.

     

    (3)This percentage is calculated based upon 47,036,698 shares of Common Stock outstanding as of May 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024.

     

     

     

    CUSIP No.   29337E102
    1.

    Names of Reporting Persons

    Andrew J. Schwab

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)  ¨

    (b)  x (1)

    3. SEC Use Only
    4.

    Source of Funds (See Instructions)

    AF

    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)    ¨
    6.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    2,304,332 shares (2)

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    2,304,332 shares (2)

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,304,332 shares (2)

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    ¨
    13.

    Percent of Class Represented by Amount in Row (11)

    4.9% (3)

    14.

    Type of Reporting Person (See Instructions)

    IN

           

    (1)This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     

    (2)Includes (i) 1,922,673 shares of Common Stock held by Ventures VI and (ii) 381,659 shares of Common Stock held by Opportunities. Partners VI serves as the sole general partner of Ventures VI and Opportunities GP serves as the sole general partner of Opportunities. As managing members of each of Partners VI and Opportunities GP, Schwab and Parmar share voting and dispositive power over the shares held by each of Ventures VI and Opportunities.

     

    (3)This percentage is calculated based upon 47,036,698 shares of Common Stock outstanding as of May 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024.

     

     

     

    Explanatory Note: This Amendment No. 5 (“Amendment No. 5”), which amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2023, as amended on August 28, 2023, February 2, 2024, February 16, 2024 and April 15, 2024 (the “Original Schedule 13D”) on behalf of 5AM Ventures VI, L.P. (“Ventures VI”), 5AM Partners VI, LLC (“Partners VI”), 5AM Opportunities I, L.P. (“Opportunities”), 5AM Opportunities I (GP), LLC (“Opportunities GP”), Andrew J. Schwab (“Schwab”) and Dr. Kush Parmar (“Parmar” and, with Ventures VI, Partners VI, Opportunities, Opportunities GP and Schwab, collectively, the “Reporting Persons”) relates to the Common Stock, par value $0.001 per share (“Common Stock”) of Enliven Therapeutics, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 5 is being filed by the Reporting Persons to report sales of Common Stock. Accordingly, the number of securities beneficially owned by the Reporting Persons has decreased as described in Items 4 and 5 below.

     

    Items 4 and 5 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

     

    Item 4.Purpose of Transaction

     

    Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end of Item 4:

     

    On July 12, 2024, Ventures VI sold an aggregate of 66,750 shares of Common Stock and Opportunities sold an aggregate of 13,250 shares of Common Stock each in open market transactions at prices ranging from $24.65 to $25.27 per share (a weighted-average price of $24.96 per share).

     

    On July 15, 2024, Ventures VI sold an aggregate of 125,156 shares of Common Stock and Opportunities sold an aggregate of 24,844 shares of Common Stock each in open market transactions at prices ranging from $24.65 to $25.23 per share (a weighted-average price of $24.82 per share).

     

    On July 16, 2024, Ventures VI sold an aggregate of 5,459 shares of Common Stock and Opportunities sold an aggregate of 1,084 shares of Common Stock each in open market transactions at prices ranging from $25.00 to $24.40 per share (a weighted-average price of $25.06 per share).

     

    On July 25, 2024, Ventures VI sold an aggregate of 58,406 shares of Common Stock and Opportunities sold an aggregate of 11,594 shares of Common Stock each in open market transactions at prices ranging from $24.65 to $24.78 per share (a weighted-average price of $24.66 per share).

     

    Item 5.Interest in Securities of the Issuer

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) – (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of July 25, 2024:

     

    Reporting Persons  Shares
    Held
    Directly
       Sole Voting
    Power
       Shared
    Voting
    Power
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Beneficial
    Ownership
       Percentage
    of Class (3)
     
    Ventures VI   1,922,673    0    1,922,673    0    1,922,673    1,922,673    4.1%
    Partners VI (1)   0    0    1,922,673    0    1,922,673    1,922,673    4.1%
    Opportunities   381,659    0    381,659    0    381,659    381,659    0.8%
    Opportunities GP (2)   0    0    381,659    0    381,659    381,659    0.8%
    Schwab (1) (2)   0    0    2,304,332    0    2,304,332    2,304,332    4.9%
    Parmar (1) (2)   0    0    2,304,332             0    2,304,332    2,304,332    4.9%

     

     

     

    (1)Includes 1,922,673 shares of Common Stock directly held by Ventures VI. Partners VI serves as sole general partner of Ventures VI and Schwab and Parmar are managing members of Partners VI. Each of Partners VI, Schwab and Parmar shares voting and dispositive power over the shares held by Ventures VI.

     

    (2)Includes 381,659 shares of Common Stock directly held by Opportunities. Opportunities GP serves as sole general partner of Opportunities and Schwab and Parmar are managing members of Opportunities GP. Each of Opportunities GP, Schwab and Parmar shares voting and dispositive power over the shares held by Opportunities.

     

    (3)This percentage is calculated based upon 47,036,698 shares of Common Stock outstanding as of May 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024.

     

    (c)Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

     

    (d)No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)The Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on July 25, 2024.

     

    Item 7.Material to be Filed as Exhibits

     

    A.Joint Filing Agreement, dated March 6, 2023 (incorporated by reference to the Original Schedule 13D, filed on March 6, 2023).

     

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 29, 2024

     

    5AM Ventures VI, L.P.  
       
    By: 5AM Partners VI, LLC  
    its General Partner  
       
    By: /s/ Andrew J. Schwab  
      Name: Andrew J. Schwab  
      Title: Managing Member  
       
    5AM Partners VI, LLC  
       
    By: /s/ Andrew J. Schwab  
      Name: Andrew J. Schwab  
      Title: Managing Member  
       
    5AM Opportunities I, L.P.  
       
    By: 5AM Opportunities I (GP), LLC  
    its General Partner  
       
    By: /s/ Andrew J. Schwab  
      Name: Andrew J. Schwab  
      Title: Managing Member  
       
    5AM Opportunities I (GP), LLC  
       
    By: /s/ Andrew J. Schwab  
      Name: Andrew J. Schwab  
      Title: Managing Member  
       
    /s/ Andrew J. Schwab  
    Andrew J. Schwab  
       
    /s/ Dr. Kush Parmar  
    Dr. Kush Parmar  

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

    Get the next $ELVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELVN

    DatePrice TargetRatingAnalyst
    12/13/2024$42.00Buy
    BTIG Research
    9/9/2024$37.00Buy
    H.C. Wainwright
    6/11/2024$32.00Outperform
    Robert W. Baird
    4/9/2024$34.00Buy
    Mizuho
    3/29/2023$27.00Buy
    Jefferies
    3/3/2023Outperform
    TD Cowen
    More analyst ratings

    $ELVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

      Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 patients enrolled Enliven to host a webcast and conference call following the oral presentation at EHA on Friday, June 13, at 1:30 p.m. ET Strong balance sheet with $290 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2027 BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clini

      5/14/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

      Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff Presentation at EHA will include updated data with additional patients and longer treatment duration Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage bi

      5/14/25 9:56:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

      BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Poster Presentation Details  Abstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:

      4/2/25 4:03:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:48:35 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:46:11 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 4:24:01 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Enliven Therapeutics Inc.

      10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)

      5/14/25 4:15:33 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

      5/14/25 4:10:10 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Enliven Therapeutics Inc.

      DEFA14A - Enliven Therapeutics, Inc. (0001672619) (Filer)

      4/28/25 4:08:39 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF OPERATING OFFICER Patel Anish sold $122,579 worth of shares (6,667 units at $18.39) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/9/25 6:48:38 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $150,391 worth of shares (7,500 units at $20.05) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/5/25 6:43:44 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Kintz Samuel sold $150,415 worth of shares (7,500 units at $20.06) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/5/25 6:42:17 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Financials

    Live finance-specific insights

    See more
    • Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

      Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, and ELVN-001 remains well-tolerated with 74 patients enrolled Enliven to host a webcast and conference call following the oral presentation at EHA on Friday, June 13, at 1:30 p.m. ET Strong balance sheet with $290 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2027 BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clini

      5/14/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

      Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff Presentation at EHA will include updated data with additional patients and longer treatment duration Enliven will host a webcast and conference call on June 13 at 1:30 p.m. ET BOULDER, Colo., May 14, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage bi

      5/14/25 9:56:00 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Enliven Therapeutics with a new price target

      BTIG Research initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $42.00

      12/13/24 7:38:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Enliven Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

      9/9/24 7:29:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Enliven Therapeutics with a new price target

      Robert W. Baird initiated coverage of Enliven Therapeutics with a rating of Outperform and set a new price target of $32.00

      6/11/24 7:13:48 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

      BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e

      4/9/24 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care